MedTrace Logo

European Study of HF0220 in Mild to Moderate Alzheimer's Disease Patients

NCT00357357 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2008-08-21

No results posted yet for this study

Summary

The purpose of this Phase II study is to evaluate the safety and tolerability of HF 0220 in patients with Alzheimer's disease compared to placebo (inactive substance). The study will also validate biochemical markers as appropriate clinical end-points and to assess the suitability of chosen dose levels for future clinical studies.

Conditions

Interventions

DRUG

HF0220

comparison of different dosages of drug

Sponsors & Collaborators

  • Hunter-Fleming Ltd

    lead INDUSTRY

Principal Investigators

  • David Wilkinson · Chief Principal Investigator

  • Niels Andreasen, Dr · Swedish Co-Ordinating Principal Investigator

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • India
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00357357 on ClinicalTrials.gov